Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Cash & Equivalents (2016 - 2025)

Altimmune (ALT) has disclosed Cash & Equivalents for 16 consecutive years, with $61.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 94.43% to $61.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $61.3 million, a 94.43% increase, with the full-year FY2024 number at $37.0 million, down 72.65% from a year prior.
  • Cash & Equivalents was $61.3 million for Q3 2025 at Altimmune, down from $183.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $190.3 million in Q4 2021 to a low of $31.5 million in Q3 2024.
  • A 5-year average of $114.3 million and a median of $111.1 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 1226.04% in 2021, then plummeted 72.65% in 2024.
  • Altimmune's Cash & Equivalents stood at $190.3 million in 2021, then tumbled by 41.61% to $111.1 million in 2022, then increased by 21.62% to $135.2 million in 2023, then tumbled by 72.65% to $37.0 million in 2024, then soared by 65.76% to $61.3 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Cash & Equivalents are $61.3 million (Q3 2025), $183.1 million (Q2 2025), and $49.1 million (Q1 2025).